IL151911A0 - Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them - Google Patents
Pyrolidine derivatives, their preparation and pharmaceutical compositions containing themInfo
- Publication number
- IL151911A0 IL151911A0 IL15191101A IL15191101A IL151911A0 IL 151911 A0 IL151911 A0 IL 151911A0 IL 15191101 A IL15191101 A IL 15191101A IL 15191101 A IL15191101 A IL 15191101A IL 151911 A0 IL151911 A0 IL 151911A0
- Authority
- IL
- Israel
- Prior art keywords
- pyrrolidine derivatives
- formula
- group
- preparation
- bax
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00106033 | 2000-03-27 | ||
PCT/EP2001/003170 WO2001074769A1 (en) | 2000-03-27 | 2001-03-20 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL151911A0 true IL151911A0 (en) | 2003-04-10 |
Family
ID=8168168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15191101A IL151911A0 (en) | 2000-03-27 | 2001-03-20 | Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them |
Country Status (13)
Country | Link |
---|---|
US (1) | US7018988B2 (de) |
EP (1) | EP1268418B1 (de) |
JP (1) | JP2003529584A (de) |
AT (1) | ATE329899T1 (de) |
AU (2) | AU2001252222B2 (de) |
CA (1) | CA2401137A1 (de) |
DE (1) | DE60120661T2 (de) |
DK (1) | DK1268418T3 (de) |
ES (1) | ES2262640T3 (de) |
IL (1) | IL151911A0 (de) |
PT (1) | PT1268418E (de) |
SI (1) | SI1268418T1 (de) |
WO (1) | WO2001074769A1 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2261404T3 (es) * | 2000-03-27 | 2006-11-16 | Applied Research Systems Ars Holding N.V. | Derivados de pirrolidina utiles como inhibidores de bax. |
MXPA03003039A (es) * | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
US6809093B2 (en) * | 2000-10-17 | 2004-10-26 | H. Lee Moffitt Cancer & Research Institute, Inc. | 2-substituted heterocyclic compounds |
AU2002248180A1 (en) * | 2000-12-14 | 2002-07-16 | The Burnham Institute | Non-apoptotic forms of cell death and methods of modulation |
EA006212B1 (ru) | 2001-06-18 | 2005-10-27 | Апплайд Резеч Системз Арс Холдинг Н.В. | Оксадиазольные и тиадиазольные производные пирролидина |
US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
US20030157053A1 (en) * | 2002-02-19 | 2003-08-21 | Sabina Sperandio | Modulators of paraptosis and related methods |
TWI403320B (zh) * | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
EP2040698A4 (de) * | 2006-07-14 | 2011-08-10 | Shionogi & Co | Oximverbindungen und ihre verwendung |
KR100979102B1 (ko) | 2007-03-13 | 2010-08-31 | (주)바이오솔로몬 | 사이토크롬 p450 2E1의 활성 억제 또는 사이토크롬p450 3A4의 활성 증가 효과를 갖는 BI-1단백질을 포함하는 조성물 및 이의 용도 |
US9095572B2 (en) | 2009-01-09 | 2015-08-04 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US8604074B2 (en) | 2009-01-09 | 2013-12-10 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US8362277B2 (en) * | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
KR100989045B1 (ko) | 2010-01-11 | 2010-10-25 | (주)바이오솔로몬 | 사이토크롬 p450 3A4의 활성 저하로 효능이 감소되는 약물의 활성을 증가시키는 효과를 갖는 BI-1 단백질을 포함하는 조성물 및 이의 용도 |
KR101680302B1 (ko) * | 2010-07-13 | 2016-11-29 | 김찬숙 | 세포의 다핵분열을 유도할 수 있는 조성물 |
EP2759533B1 (de) * | 2011-09-22 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Kondensierte heterocyclische verbindung |
WO2013055949A2 (en) | 2011-10-11 | 2013-04-18 | Dana Farber Cancer Institute, Inc. | Pyrazol-3-ones that activate pro-apoptotic bax |
WO2014031986A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
EP2845850A1 (de) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidinderivate als Oxytocin/Vasopressin-V1a-Rezeptorantagonisten |
EP3068388A4 (de) | 2013-11-11 | 2017-04-12 | Board of Regents of the University of Texas System | Nervenschützende verbindungen und verwendung davon |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
EP2886107A1 (de) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Orale Formulierungen von Pyrrolydinderivaten |
JP2017519015A (ja) | 2014-07-02 | 2017-07-13 | オブセヴァ エス.エー. | Ot−r活性に関する疾患を治療するための方法に有用な結晶質の(3z,5s)−5−(ヒドロキシメチル)−1−[(2’−メチル−1,1’−ビフェニル−4−イル)カルボニル]ピロリジン−3−オン о−メチルオキシム |
WO2022051384A1 (en) * | 2020-09-01 | 2022-03-10 | Albert Einstein College Of Medicine | Compounds and methods for inhibition of bax-mediated cell death |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL23907A (en) | 1964-08-05 | 1971-05-26 | Upjohn Co | Lincomycin analogues and a process for their production |
US3555007A (en) | 1968-07-22 | 1971-01-12 | Upjohn Co | 7-deoxy-7-halo lincomycin d derivatives |
US3674647A (en) | 1970-10-07 | 1972-07-04 | Upjohn Co | Preparation of lincomycin analogues |
ZA801424B (en) * | 1979-03-12 | 1981-03-25 | Warner Lambert Co | Novel antibactrial amide compounds and process means for producing the same |
US4278681A (en) * | 1979-03-12 | 1981-07-14 | Warner-Lambert Co. | Antibacterial amide compounds and means for using the same |
US4596819A (en) * | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
US4851514A (en) * | 1987-05-01 | 1989-07-25 | E. R. Squibb & Sons, Inc. | Process for preparing a compound useful in preparing ace inhibitors and intermediate produced thereby |
US4734508A (en) * | 1987-05-01 | 1988-03-29 | E. R. Squibb & Sons, Inc. | Process and intermediates for preparing 4-substituted proline derivatives |
US5514683A (en) * | 1992-02-20 | 1996-05-07 | James Black Foundation Limited | Bicyclo 2,2,2!octane derivatives |
ATE152095T1 (de) * | 1992-02-20 | 1997-05-15 | Black James Foundation | Bicyclo(2.2.2.>oktan derivate als cholestocystokinin harnstoffe |
GB9316162D0 (en) | 1993-08-04 | 1993-09-22 | Zeneca Ltd | Fungicides |
AR016133A1 (es) * | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
US6329418B1 (en) * | 1998-04-14 | 2001-12-11 | The Procter & Gamble Company | Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
KR100633349B1 (ko) * | 1998-07-14 | 2006-10-16 | 오노 야꾸힝 고교 가부시키가이샤 | 아미노산 유도체 및 이들을 유효 성분으로서 함유하는 약제 |
DE69921147T2 (de) | 1998-08-07 | 2005-02-24 | Applied Research Systems Ars Holding N.V. | Fsh mimetika zur behandlung von infertilität |
CN1353701A (zh) * | 1999-01-27 | 2002-06-12 | 奥索-麦克尼尔药品公司 | 用作类胰蛋白酶抑制剂的肽基杂环酮类化合物 |
WO2000048623A1 (en) * | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
CA2368148A1 (en) * | 1999-03-15 | 2000-09-21 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
DE60026514T2 (de) * | 1999-05-05 | 2006-11-09 | Merck & Co., Inc. | Neue prolinverbindungen als mikrobizide mittel |
GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
ES2261404T3 (es) * | 2000-03-27 | 2006-11-16 | Applied Research Systems Ars Holding N.V. | Derivados de pirrolidina utiles como inhibidores de bax. |
-
2001
- 2001-03-20 SI SI200130565T patent/SI1268418T1/sl unknown
- 2001-03-20 AU AU2001252222A patent/AU2001252222B2/en not_active Ceased
- 2001-03-20 AT AT01925491T patent/ATE329899T1/de active
- 2001-03-20 IL IL15191101A patent/IL151911A0/xx unknown
- 2001-03-20 JP JP2001572464A patent/JP2003529584A/ja not_active Withdrawn
- 2001-03-20 CA CA002401137A patent/CA2401137A1/en not_active Abandoned
- 2001-03-20 WO PCT/EP2001/003170 patent/WO2001074769A1/en active IP Right Grant
- 2001-03-20 PT PT01925491T patent/PT1268418E/pt unknown
- 2001-03-20 AU AU5222201A patent/AU5222201A/xx active Pending
- 2001-03-20 US US10/240,000 patent/US7018988B2/en not_active Expired - Fee Related
- 2001-03-20 DE DE60120661T patent/DE60120661T2/de not_active Expired - Lifetime
- 2001-03-20 ES ES01925491T patent/ES2262640T3/es not_active Expired - Lifetime
- 2001-03-20 EP EP01925491A patent/EP1268418B1/de not_active Expired - Lifetime
- 2001-03-20 DK DK01925491T patent/DK1268418T3/da active
Also Published As
Publication number | Publication date |
---|---|
DE60120661D1 (de) | 2006-07-27 |
US7018988B2 (en) | 2006-03-28 |
PT1268418E (pt) | 2006-08-31 |
EP1268418A1 (de) | 2003-01-02 |
SI1268418T1 (sl) | 2006-10-31 |
DE60120661T2 (de) | 2007-07-05 |
CA2401137A1 (en) | 2001-10-11 |
AU2001252222B2 (en) | 2006-11-02 |
US20030171309A1 (en) | 2003-09-11 |
EP1268418B1 (de) | 2006-06-14 |
DK1268418T3 (da) | 2006-09-25 |
ATE329899T1 (de) | 2006-07-15 |
JP2003529584A (ja) | 2003-10-07 |
WO2001074769A1 (en) | 2001-10-11 |
AU5222201A (en) | 2001-10-15 |
ES2262640T3 (es) | 2006-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL151911A0 (en) | Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them | |
ATE478058T3 (de) | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung | |
TW200640900A (en) | 1-(2h)-isoquinolone derivative | |
WO2002000650A3 (en) | Novel compounds possessing antibacterial, antifungal or antitumor activity | |
CA2510853A1 (en) | Pyrrolopyrimidine derivatives | |
HRP20050830A2 (en) | Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases | |
MX2007004979A (es) | Derivados de indol tetraciclicos como agentes antiviricos. | |
GEP201706611B (en) | Amido compounds and their use as pharmaceuticals | |
WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
WO2006024486A3 (en) | Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents | |
HUP0302792A2 (hu) | Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
CA2383555A1 (en) | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents | |
CA2290918A1 (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
TW200616636A (en) | Novel compounds | |
AR070518A1 (es) | 4-oxo-naftiridinas y 4-oxo-1,4-dihidroquinolinas, composiciones farmaceuticas y kits que los comprenden y su uso para el tratamiento de infecciones virales. | |
SE0302192D0 (sv) | Novel compounds | |
WO2007143523A3 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
TW200612965A (en) | Methods for preparing p2x7 inhibitors | |
DE602005018972D1 (de) | 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren | |
YU73502A (sh) | Farmaceutski aktivni derivati pirolidina | |
ATE429429T1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
MXPA02012409A (es) | Derivados de pirrol para tratamiento del sida. | |
ATE371644T1 (de) | Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung | |
CA2470037A1 (en) | Prodrugs to d-prolines | |
CA3242000A1 (en) | Fused heteroaryl hydroxamates as sting agonists |